News

Oleolive awarded NIH funding to study oleocanthal and alzheimers

Oleolive awarded NIH funding to study oleocanthal and alzheimers
Oleolive is incredibly excited to announce our award by the NIH (National Institutes of Health) and NIA (National Institue on Aging) to further our...

The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer recurrence

Authors: Abu Bakar Siddique, Hassan Ebrahim, Mohamed Mohyeldin, Seetharama D. Jois and Khalid A. El Sayed Abstract: Dysregu...

Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer's disease.

Authors: Batarseh YS1, Kaddoumi A2. Abstract:   Previous evidence suggested that extra-virgin olive oil (EVOO) is linked to attenu...

OLIGEN approved by INCI as first Trade Name for Oleocanthal

As part of Oleolive’s intellectual property strategy, the name OLIGEN was trademarked as the company’s brand of oleocanthal. Subsequently, up...

Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model.

Authors: Qosa H1, Batarseh YS1, Mohyeldin MM1, El Sayed KA1, Keller JN2, Kaddoumi A1. Abstract: Numerous clinical and preclinical studi...

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor.

Authors: Mohyeldin MM1, Akl MR1, Ebrahim HY1, Dragoi AM2, Dykes S2, Cardelli JA2, El Sayed KA1. Abstract: The hepatocyte growth...

Oleocanthal ameliorates amyloid-β oligomers' toxicity on astrocytes and neuronal cells: In vitro studies.

Authors: Batarseh YS1, Mohamed LA1, Al Rihani SB1, Mousa YM1, Siddique AB1, El Sayed KA1, Kaddoumi A2. Abstract: Extra-virgin o...

The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.

Authors: Ayoub NM1, Siddique AB2, Ebrahim HY2, Mohyeldin MM2, El Sayed KA2 Abstract: Luminal breast cancer represents a therape...